Company profile: Prelude Therapeutics
1.1 - Company Overview
Company description
- Provider of small-molecule cancer therapies and precision antibody-drug conjugates, including PRT3789, a selective SMARCA2 degrader for SMARCA4-deficient tumors; PRT2527, a highly selective CDK9 inhibitor in Phase 1; PRT3645, a next-generation CDK4/6 inhibitor in preclinical studies; and ADCs developed with AbCellera.
Products and services
- PRT2527: A clinical-stage, highly selective CDK9 inhibitor aimed at cancers dependent on CDK9, currently in Phase 1 clinical trials in CDK9-dependent malignancies
- PRT3789: A selectivity-optimized, potent SMARCA2 degrader engineered for high selectivity over SMARCA4, targeting SMARCA4-deficient tumors with precise activity against cancers lacking SMARCA4
- Precision ADCs: Partnership-developed antibody-drug conjugates engineered for antigen-specific tumor targeting, created with AbCellera to focus binding on tumor-specific antigens
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Prelude Therapeutics
Verastem
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies targeting RAS/MAPK pathway–driven cancers, developing avutometinib, a RAF/MEK clamp designed to block RAF and MEK signaling in the RAS pathway, and defactinib, a FAK inhibitor used with avutometinib to block compensatory FAK activation and enhance tumor growth blockade.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Verastem company profile →
Medfusion Services
HQ: United States
Website
- Description: Provider of integrated clinical laboratory and clinical trial services, offering diagnostic testing (solid tumor, hematopathology, women's health, urology, general health), molecular diagnostics and test development, pathology services, and clinical trial support including specimen collection, processing, testing, and guidance for specimen packaging and shipping.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medfusion Services company profile →
Novelos Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical research, development, and commercialization focused on oxidized glutathione.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Novelos Therapeutics company profile →
Highlight Therapeutics
HQ: Spain
Website
- Description: Provider of an RNA-based immuno-oncology therapy, BO-112, designed to initiate an immune response against 'cold' tumors, making them 'hot' and visible to the immune system. Services include clinical development and trials (successful Phase 1 monotherapy, Phase 1b with anti-PD1), collaborations with Merck & Co and UCLA, and R&D into BO-112’s mechanism where checkpoint inhibitors are ineffective.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Highlight Therapeutics company profile →
BioMark Diagnostics
HQ: Canada
Website
- Description: Provider of oncology-focused metabolomics-based cancer detection solutions, including a liquid biopsy metabolic panel for early lung cancer diagnosis using urine and plasma, a non-invasive SSAT1 assay leveraging an FDA-approved drug to detect elevated enzyme levels in cancers, a metabolomics-driven detection platform, lung cancer early detection studies, and cancer education videos.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioMark Diagnostics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Prelude Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Prelude Therapeutics
2.2 - Growth funds investing in similar companies to Prelude Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Prelude Therapeutics
4.2 - Public trading comparable groups for Prelude Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →